Korean J Intern Med.  2014 Sep;29(5):547-557. 10.3904/kjim.2014.29.5.547.

Recent technological updates and clinical applications of induced pluripotent stem cells

• Diecke S
• Jung SM
• Lee J
• Ju JH

• KMID: 1794617
• DOI: http://doi.org/10.3904/kjim.2014.29.5.547

Abstract

Induced pluripotent stem cells (iPSCs) were first described in 2006 and have since emerged as a promising cell source for clinical applications. The rapid progression in iPSC technology is still ongoing and directed toward increasing the efficacy of iPSC production and reducing the immunogenic and tumorigenic potential of these cells. Enormous efforts have been made to apply iPSC-based technology in the clinic, for drug screening approaches and cell replacement therapy. Moreover, disease modeling using patient-specific iPSCs continues to expand our knowledge regarding the pathophysiology and prospective treatment of rare disorders. Furthermore, autologous stem cell therapy with patient-specific iPSCs shows great propensity for the minimization of immune reactions and the provision of a limitless supply of cells for transplantation. In this review, we discuss the recent updates in iPSC technology and the use of iPSCs in disease modeling and regenerative medicine.

Keyword

Induced pluripotent stem cells; Reprogramming technique; Gene editing; Disease model; Regenerative medicine

MeSH Terms

Animals
Cellular Reprogramming
Drug Evaluation, Preclinical
Gene Targeting
Humans
Induced Pluripotent Stem Cells/*cytology/*transplantation
Mice
Models, Biological
Regenerative Medicine